Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Health
QIAGEN enhances QIAwave portfolio with new eco-friendlier
Venlo, the Netherlands, Sept. 25, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of its eco-friendlier QIAwave product line with the addition of two new nucleic acid extraction…
Gain Therapeutics to Participate at Cantor Fitzgerald
BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today…
Nuvectis Pharma Announces Updated Date and Time for the
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the…
TransCode Therapeutics Announces Pricing of $8 Million
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its…
- Advertisement -
Editas Medicine Reports Inducement Grants to New Chief
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and…
Femasys Inc. Receives U.S. FDA Clearance to Market
- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed®, an intratubal artificial insemination option designed to augment the natural fertilization process - -…
Ultragenyx Launches Evkeeza® (evinacumab for injection) in
TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today…
Profound Medical Receives U.S. FDA 510(k) Clearance for
TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the…
- Advertisement -
DIOSynVax and Ethris Publish Preclinical Proof of Concept
Successful vaccine candidate combining DIOSynVax's computational multi-virus vaccine antigen payload technology and Ethris’ proprietary non-immunogenic messenger RNA (SNIM mRNA) and lipidoid nanoparticle (SNaP LNP) platformsData…
National Institute of Health to Fund Preclinical
LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases,…